康希諾(06185.HK):正籌備將吸入用新冠疫苗推出市場 冀未來能為港供貨
康希諾(06185.HK)吸入用重組新冠病毒疫苗「克威莎霧優」獲國家藥監局組織論證同意作為加強針納入緊急使用。公司董事長兼首席執行官宇學峰接受《信報》訪問時指出,正密鑼緊鼓籌備把產品推出市場,並正持續與本港政府、專家溝通,期望未來能為本港供貨。
他稱,由於吸入用新冠疫苗的接種劑量只是注射的五分一,產能可提供足夠支持,「霧優」將由內地政府統一採購,不便披露定價。而吸入用疫苗是一種新的給藥形式,在設備使用、人員培訓等亦需要時間安排。
他又指,雖然目前全球疫苗市場供過於求,但由於新冠將「流感化」,料新冠病毒將伴隨人類長期存在,因此應為長期使用新冠疫苗的可能性做好準備,而吸入用疫苗在使用上更便捷,是其中一項優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.